Robert Wasserman
Stock Analyst at Benchmark
(3.31)
# 1,027
Out of 5,008 analysts
109
Total ratings
48.57%
Success rate
3%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $65.81 | +36.76% | 10 | Sep 24, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $4 → $1.5 | $0.28 | +435.71% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $59.04 | +27.03% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $6.62 | +126.59% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.66 | +261.45% | 9 | May 12, 2025 | |
| ITGR Integer Holdings | Maintains: Buy | $150 → $140 | $104.29 | +34.24% | 11 | Apr 25, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $37.47 | -6.59% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $5.75 | - | 6 | Mar 3, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $26.37 | +13.77% | 6 | Dec 19, 2024 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $2.35 | +240.44% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $5.81 | -13.94% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $9.88 | +21.46% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.56 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $145.66 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $50.09 | -10.16% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.27 | -6.32% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.36 | +1,004.67% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $3.05 | +2,359.02% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $208.68 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $539.14 | +7.58% | 1 | Jul 16, 2021 |
Halozyme Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $75 → $90
Current: $65.81
Upside: +36.76%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4 → $1.5
Current: $0.28
Upside: +435.71%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $59.04
Upside: +27.03%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $6.62
Upside: +126.59%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.66
Upside: +261.45%
Integer Holdings
Apr 25, 2025
Maintains: Buy
Price Target: $150 → $140
Current: $104.29
Upside: +34.24%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $37.47
Upside: -6.59%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $5.75
Upside: -
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $26.37
Upside: +13.77%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.35
Upside: +240.44%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $5.81
Upside: -13.94%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $9.88
Upside: +21.46%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.56
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $145.66
Upside: -
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $50.09
Upside: -10.16%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.27
Upside: -6.32%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.36
Upside: +1,004.67%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $3.05
Upside: +2,359.02%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $208.68
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $539.14
Upside: +7.58%